Article
NUAK family kinase 2 is a novel therapeutic target for prostate cancer
24 Nov 2021
Abstract excerpt
Current advancements in prostate cancer (PC) therapies have been successful in slowing PC progression and increasing life expectancy; however, there is still no curative treatment for advanced metastatic castration resistant PC (mCRPC). Most treatment options target the androgen receptor, to which many PCs eventually develop resistance. Thus, there is a dire need to identify and validate new molecular targets for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
